natgillin/translations-raw huggingface dataset:
The method of any preceding claim, characterised by applying a coating (2300) over said dosage of active agent (2000) on each of said plurality of carrier substrates (1000) and/or applying an identification marker to each of said plurality of carrier substrates (1000). 
Uređaj (10) u skladu s patentnim zahtjevom 8, naznačen time što navedeni sustav za oblaganje (600) ima napravu za prskanje koja naprska navedena obloga (2300) na svaku od nosivih tableta (1000).
a light chain variable region comprising the amino acid sequence of SEQ ID NO: 80, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NOs: 87, 88 or 89; or 
(a) varijabilno područje lakog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 80; i varijabilno područje teškog lanca koje obuhvaća aminokiselinsku sekvencu iz SEQ ID NO: 87, SEQ ID NO: 88 ili SEQ ID NO:89; ili
The processing of extracted oils (triglycerides) is usually carried out by hydrolysis to acids or by transesterification to esters; acids and esters can be used as such or undergone to chemical modification according to methods known in the art, to give a wide range of derivatives. 
Procesuiranje ekstrahiranih ulja (triglicerida) se obično izvodi hidrolizom do kiselina ili transesterifikacijom do estera; kiseline 1 esteri se mogu upotrijebiti kao takvi ili podvrći kemijskoj modifikaciji prema postupcima koji su poznati u struci, da se dobije širok opseg derivata.
For example, in some embodiments, there is provided a method of treating a platinum-sensitive recurrent ovarian, peritoneal, or fallopian tube cancer in the individual, comprising administering to the individual an effective amount of Nab-paclitaxel or Abraxane®. 
(b) djelotvornu količinu sredstva na bazi platine, namijenjenu upotrebi u postupku liječenja recidiva raka jajnika, peritoneuma ili jajovoda kod osobe, gdje je osoba prethodno primila kemoterapiju i ima interval bez liječenja dulji od otprilike tri mjeseca prije početka liječenja.
A preventive or therapeutic agent for transient ischemic attack, diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, connective tissue disease, reocclusion / restenosis after percutaneous transluminal coronary angioplasty (PTCA), arteriosclerosis, thrombosis, hypertension, pulmonary hypertension, ischemic disorder, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, allergy, bronchial asthma, ulcer, pressure ulcer (bedsore), restenosis after coronary intervention such as atherectomy and stent implantation, thrombocytopenia by dialysis, the diseases in which fibrosis of organs or tissues is involved, erectile dysfunction, inflammatory bowel disease, gastritis, gastric ulcer, ischemic ophthalmopathy, sudden hearing loss, avascular necrosis of bone, intestinal damage caused by administration of a non-steroidal anti-inflammatory agent, and symptoms associated with lumbar spinal canal stenosis, comprising the crystal of any one of claims 1 to 3 as an active ingredient. 
Spoj, naznačen time što je namijenjen upotrebi u liječenju dijabetične neuropatije, dijabetične gangrene, poremećaja perifernog krvotoka, kroničnog začepljenja arterija, povremenog šepanja, tromboze, plućne hipertenzije, infarkta miokarda, angine, glomerulonefritisa, dijabetične nefropatije, kronične insuficijencije bubrega, bronhijalne astme, intersticijske pneumonije (plućne fibroze), skleroderme, kronične opstruktivne plućne bolesti, upalne bolesti crijeva, tubulointersticijskog nefritisa, ili simptoma povezanih s lumbalnom stenozom kralježničnog kanala, gdje je spoj kristal u skladu s patentnim zahtjevom 1. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje plućne hipertenzije. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje poremećaja perifernog krvotoka.
mixing nickel hydroxide with an iron source and slagging agents to produce a mixture, wherein the iron source comprises iron ore or metallic agent; 
Postupak proizvodnje sirovog feronikal proizvoda, obuhvaća sljedeće korake: (1) miješanje niklovog hidroksida s izvorom željeza i agensom troske;
treatment of male castrated rabbits. 
davanja kastriranim mužjacima kunića.
The process according to any of claims 1 to 22, characterised in that the C8 to C24 aliphatic monocarboxylic acid of the Group II or Group III salt(s) of a C8 to C24 aliphatic monocarboxylic acid employed in step (a) and the C8 to C24 aliphatic carboxylic acid(s) employed in step (b) are not equivalent. 
Postupak prema bilo kojem od zahtjeva 1 do 12, naznačen time da C8 do C24 alifatska monokarboksilna kiselina Skupine II- ili Skupine III-soli C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) 1 C8 do C24 alifatska karboksilna kiselina odnosno alifatske karboksilne kiseline koje se koriste u koraku (b) nisu ekvivalentne.
The compound of claim 1, wherein R2 is selected from the group consisting of halogen and C1-4alkyl, wherein alkyl is optionally perfluorinated. 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koja sadrži halogen i C1-4alkil, gdje je alkil opcijski fluoriziran.
PTA-7045 to human TNFa; and (ii) binds to a neutralizing epitope of human TNFa with an affinity of at least 1 x 108 liter/mole, measured as an association constant (Ka). 
PTA-7045 za ljudski TNFoa; 1 (1i) veže se za neutralizirajući epitop ljudskog TNFo. s afinitetom od najmanje 1 x 10* litara/molu, mjereno kao konstanta asocijacije (Ka).
A pharmaceutical composition according to any one of claims 1-13, wherein such single dose form comprises one or more antidiabetic compounds selected from the group consisting of protein tyrosine phosphatase inhibitors, glutamine-fructose-6-phosphate amidotransferase inhibitors, glucose-6-phosphatase inhibitors, fructose-1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glucagon receptor antagonists, phosphoenolpyruvate carboxykinase inhibitors, pyruvate dehydrogenase kinase inhibitors, alpha-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and a2-adrenergic antagonists. 
Farmaceutska kompozicija proma bilo kojem od patentnih zahtjeva 1-13, naznačena time što takav pojedinačni dozni oblik sadrži jedan ili više antidijabetičnih spojeva koji su izabrani iz grupe koju čine inhibitori protein tirozin fosfataze, inhibitori glutamin-fruktoza-6-fosfat amidotransferaze, inhibitori glukoza-6-fosfataze, inhibitori fruktoza-1,6-bisfosfataze, inhibitori glikogen fosforilaze, antagonisti receptora za glukagon, inhibitori fosfoenolpiruvat karboksikinaze, inhibitori piruvat dehidrogenaza kinaze, inhibitori alfa-glukozidaze, inhibitori pražnjenja želuca, insulin i o2-adrenergični antagonisti.
A compound of formula:, or a pharmaceutically acceptable salt or solvate thereof. 
Spoj sa formulom: [image] ili njegova farmaceutski prihvatljiva sol ili solvat.
Process for the preparation of a compound of the formula (I): 
Postupak proizvodnje spoja formule (V):
The method according to claim 9, wherein a reach of spray of the individual spray heads is being inspected, by registering a cone and/or cloud of smoke and/or mist exiting from the spray head. 
Postupak sukladno zahtjevima 9 ili 10, pri čemu je doseg spreja individualnih štrealjki (17A-E) ispitivan, registriranjem stošca i/ili oblaka dima koji izlazi iz štrcaljke. 12.
The flasks were incubated at approximately 37° C. in a humidified atmosphere of approximately 5% CO2 in air for 16-24 hr. 
Bočice su inkubirane na približno 37%C u vlažnoj atmosferi od približno 5% CO, u zraku 16-24 sata.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in claims 1 or 2. 
Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu spoja opće formule (21) ifili njegove soli ili stereoizomera kao što je definirano u patentnim zahtjevima 1-6.
thermal gravimetric analysis curve with about 18.7% weight loss from about room temperature up to about 240°C or as shown in Figure 5; or 
krivulju toplinske gravimetrijske analize s oko 18.7% gubitka težine od sobne temperature do oko 240°C ili kako je prikazano na slici 5; ili
In the first stage of the study a psuedoarthrosis model was developed. 
(32) Datum podnošenja prve prijave: 26.02.2008.
and R4 in combination with the nitrogen to which they are attached form a cyclic moiety selected from morpholino or pyrrolidinyl. 
R* i R* u kombinaciji s dušikom na koji su vezani tvore cikličku skupinu odabranu od morfolino, pirolidinila ili piperazinila.
The dermal micro-organ according to any one of claims 1-4, wherein said dermal micro-organ includes at least part of the cross-section of the dermis. 
Genetički modificiran dermalni mikroorgan iz bilo kojeg od patentnih zahtjeva 1 - 3, naznačen time, da najmanje jedan navedeni rekombinantni genski produkt nije prirodno proizveden u organu iz kojeg dermalni mikroorgan potječe.
Fig. 2 shows components of the extraction module, 
Slika 2 - prikazuje komponente ovog modula za ekstrakciju,
s is 0, 1 or 2; provided that when s is 2, R1 is independently selected from the group consisting of phenyl, C1-3alkyl, and C6-1aryl(C1-3)alkyl; 
s je 0, 1 ili 2; pod uvjetom da kada je s 2, R1 je nezavisno izabran iz grupe koju čine fenil, C1-3alkil, i C6-1aril(C1-3)alkil;
X- denotes an anion with a single negative charge, preferably an anion which is selected from among chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate, optionally in form of the hydrates and/or solvates thereof, for the manufacture of a medicament for the treatment of asthma in the severity GINA step 3. 
X. označava anion s pojedinačnim negativnim nabojem, povoljno je da je anion izabran iz skupine koju čine klorid, bromid, jodid, sulfat, fosfat, metansulfonat, nitrat, maleat, acetat, citrat, fumarat, tartarat, oksalat, sukcinat, benzoat i p-toluensulfonat, po izboru u obliku njihovih hidrata i/ili solvata, za izradu lijeka za liječenje astme jačine GINA stupanj 3.
the first constituent is a glycosaminoglycan, a hydrolyzed glycosaminoglycan, a glycosamine, chemically modified or not or a blend of different glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, chemically modified or not; 
spomenuti prvi sastojak je glikozaminoglikan, hidrolizirani glikozaminoglikan, glikozamin, kemijski modificirani ili ne ili mješavina različitih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina, kemijski modificiranih ili ne;
Separation # 1 uses CAPTO ADHERE as the mixed mode chromatography resin and Separation # 2 uses CAPTO ADHERE as the mixed mode chromatography resin. 
Odvajanje # 1 koristi CAPTO ADHERE kao način kromatografske smole i Odvajanje # 2 koristi CAPTO ADHERE kao način kromatografske smole.
a substituted starch having a degree of substitution of at least one substituent group; an inorganic phase; and water, wherein the inorganic phase, the substituted starch and the water are mixed together to form a mixture, the inorganic phase is at least partially hydrated by the water, and the degree of substitution and the at least one substituent group are selected such that the substituted starch is not soluble during mixing at a mixing temperature but at least partially dissolves as the temperature increases during processing of the mixture and forms a film substantially dispersed throughout the organic-inorganic composite wherein the organic-inorganic composite is substantially strengthened. 
Zidna gips ploča, naznačena time, da ima jezgru od organsko-anorganskog kompozita koji sadrži sljedeću smjesu: supstituirani škrob koji nije topiv u hladnoj vodi, koji ima stupanj supstitucije između 1,5 1 2,5 masenih %, gdje je navedeni škrob supstituiran s najmanje jednom eterskom skupinom ili esterskom skupinom te ima maseni postotak krutina na viskozitetu od 1000 cps i na temperaturi od 65,6*C (150"F) u rasponu od 9 do 43%; voda; i anorganska faza koja sadrži gips, pri čemu je anorganska faza barem djelomično hidratizirana vodom, dok je supstituirani škrob prisutan kao film u biti raspršen kroz cijeli organsko-anorganski kompozit tako da se time organsko-anorganski kompozit bitno ojačava.
The use according to claim 10, characterized in that the pain is selected from inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain. 
Uporaba prema zahtjevu 10, naznačena time što je bol odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, migrenske boli i boli od raka.
The method according to claim 14 comprising dynamically adjusting down hole pressure in a manner to provide either (a) an underbalanced pressure condition in the hole; or (b) an overbalanced pressure condition in the hole; or (c) a balanced pressure condition in the hole. 
Postupak prema zahtjevu 14, koji sadrži dinamičko prilagođavanje tlaka pri dnu bušotine na način kako bi se osigurali bilo (a) pod-balansirani uvjeti laka u bušotini; ili (b) nad-balansirani uvjeti tlaka u bušotini; ili (c) balansirani uvjeti tlaka u bušotini.
The panel according to claim 1, wherein the second locking element comprises at least one outward bulge, and that the first locking element comprises at least one recess, which outward bulge is adapted to be at least partially received in a recess of an adjacent coupled panel for the purpose of realizing a locked coupling. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu drugi element (30, 69) za zaključavanje obuhvaća najmanje jednu vanjsku izbočinu i što prvi element (23, 64) za zaključavanje obuhvaća najmanje jedno udubljenje, gdje je vanjska izbočina prilagođena da bude najmanje djelomično smještena u udubljenje susjednog povezanog panela (1, 42, 43, 46, 53, 57) radi ostvarivanja zaključanog spoja.
The modified soluble FGF receptor Fc fusion of claim 1, wherein said modified soluble FGF receptor Fc fusion comprises 3 mannose residues, a mean of 1.5 to 3.0 galactose residues, a mean of 3.5 to 5 of N-acetylglucosamine residues, and a mean of 0.6 to 1 fucose residues per molecule of glycan. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što navedena modificirana fuzija između topivog FGF receptora i Fc sadrži 3 manozna ostatka, u prosjeku 1,5 do 3,0 galaktoznih ostataka, u prosjeku 3,5 do 5 N-acetilglukozaminskih ostataka, te u prosjeku 0,6 do 1 fukozni ostatak po molekuli glikana.
A method according to claim 1, wherein said fragment or variant or analogue of VWF is selected from the group consisting of the 52/48-kDa tryptic fragment of VWF; Staphylococcus aureus V-8 protease-digested VWF; VWF concentrates for therapeutic use and VWF mutants responsible for type 2N von Willebrand disease. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je navedeni fragment 1li inačica ili analog VWF odabran iz grupe koja se sastoji od triptičkog fragmenta VWF od 52/48-kDa; Staphylococcus aureus V-8 proteazom razgrađenog VWF; koncentrata VWF za terapijsku uporabu 1 VWF mutanata odgovornih za tip 2N von Willebrandove bolesti.
The combination according to claim 1, 2, 3 or 4 which is a compound selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, naznačen time što je to spoj izabran iz grupe koju čine:
The method according to any one of claims 7-9, wherein said food product is administered to said subject daily from at least one day before weaning said subject until the day of weaning said subject, preferably from at least three days before weaning said subject until the day of weaning said subject. 
Prehrambeni proizvod za primjenu sukladno zahtjevu 10, pri čemu se spomenuti prehrambeni proizvod daje spomenutom subjektu počevši od najmanje tri dana prije odlučivanja spomenutog subjekta sve do dana odlučivanja spomenutog subjekta.
The portion capsule according to claim 1, wherein the filter element includes a synthetic fibre material that has been deep drawn. 
Kapsula s porcijom (1) prema jednom od prethodnih zahtjeva, naznačena time da element filtera ima područje filtera (28) koje je predviđeno tako da bude zakrivljeno.
3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for use according to claim 10, which is prepared to be administered in an amount of about 25 mg per day for 21 days followed by seven days rest in a 28 day cycle. 
-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što ga se pripravlja za primjenu u količini od otprilike 25 mg dnevno, u trajanju od 21 dan, za čim slijedi sedmodnevni odmor, u ciklusu od 28 dana.
The compound according to claim 5, wherein A is selected from the group comprising halo, alkoxy, haloalkoxy, haloalkyl, alkyl, alkanol, cyano, phenoxy, alkylsulfonyl and (di)alkylamino. 
Spoj prema zahtjevu 5, naznačen time da se A odabire iz skupine koju sačinjavaju halo, alkoksi, haloalkoksi, haloalkil, alkil, alkanol, cijano, fenoksi, alkilsulfonil i (dijalkilamino.
It may also act as an energy source for bacteria, fungi, moulds and yeasts. 
Može poslužiti i kao izvor energije za bakterije, gljivice, plijesni 1 kvasce.
Thus, filthy water may flow into said distal open end, along the outer surface of the endoscopic instrument and out through the outlet. 
Dakle, nečista voda može teći u navedeni udaljeniji otvoreni kraj, duž vanjske površine endoskopskog instrumenta i zatim van kroz izlazni otvor.
A method as claimed in Claim 8 or Claim 9, wherein the pH of the inner coating preparation is adjusted to be from pH 7.5 to pH 10. 
Postupak sukladno patentnim zahtjevima 11 do 13, naznačeno time, da je pH unutarnjeg pripravka za oblaganje podešen da bude od pH 7,5 do pH 10, poželjno od pH 7,5 do pH 5,5, poželjnije oko pH 8.
A medicament according to claim 14 for the treatment of disorders which can be ameliorated by the Inhibition of human phosphodiesterase 3 and/or human phosphodlesterase 4. 
Lijek u skladu s patentnim zahtjevom 14, namijenjen liječenju poremećaja koje se može ublažiti inhibiranjem ljudske fosfodiesteraze 3 i/ili ljudske fosfodiesteraze 4.
A method as claimed in any of Claims 11 to 14, wherein the base is a hydroxide. 
Postupak sukladno patentnom jednom od patentnih zahtjeva 11 do 14, naznačeno time, da je osnova hidroksid.
The method of claim 20, wherein the compound of formula VII is precipitated as a suitable salt, e.g. 
Postupak prema zahtjevu 16, gdje se Spoj I taloži kao odgovarajuća sol, npr.
A process for the preparation of a fleece comprising steps a) and b) of the process according to any one of claims 1 to 12, characterized in that the aqueous suspension SM of flocculated filler particles obtained after process step b) is combined in a further step c) with synthetic and/or natural fibres, and the resulting suspension SMF is subjected to a dewatering step d) to obtain a fleece. 
Postupak priprave runa koji se sastoji u koracima a) i b) postupka u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što se vodenu suspenziju SM flokuliranih čestica punila dobivenih postupkom u koraku b) kombinira u daljnjem koraku c) sa sintetskim i/ili prirodnim vlaknima, a dobivenu suspenziju SMF se podvrgne koraku uklanjanja vode d) kako bi se dobilo runo.
to 50% by weight of at least one further copolymerizable, ethylenically unsaturated monomer with one or more carbon-carbon double bonds, in the presence of 
0 do 50% po težini najmanje jedan daljnji kopolimerizirajući, etilenski nezasićeni monomer s jednom ili više ugljik-ugljik dvostrukih veza zajedno s e.
The use of a composition of any preceding claims for the manufacture of a medicament for the treatment of organ or tissue transplant rejection, graft versus host disease, autoimmune diseases, inflammatory conditions, viral myocarditis, viral diseases caused by viral myocarditis or cancers. 
Binarna smjesa iz patentnog zahtjeva 1 za uporabu u liječenju odbacivanja transplantata organa ili tkiva, bolesti presadka protiv primatelja, autoimunih bolesti, upalnih stanja, virusnog miokarditisa, virusnih bolesti uzrokovanih virusnim miokarditisom ili raka.
A produced beverage is collected in the recess 33 and then guided to the guiding channel 27 underneath. FIG. 
Proizvedeni napitak se skuplja u udubljenju 33 i tada se vodi u kanal za vođenje 27 koji se nalazi ispod modula za ekstrakciju.
A compound according to claim 1, wherein said compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da je navedeni spoj odabran iz skupine koju čine:
Use according to any one of the preceding claims, characterized in that prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension has a temperature of between 5 and 100°C, preferably of between 35 and 85°C, and more preferably of between 45 and 75°C. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je prije dodavanja 2- ((1-metilpropiljaminojetanola, navedena otopina temperature između 5 1 100%C, poželjno između 35 1 85*C, poželjnije između 45 1 75*C.
A method for the preparation of a liquid rotavirus composition of claim 1 comprising admixing a rotavirus antigen, a sugar and a carboxylate of a di-carboxylic acid with an average pKa>4 with a pharmaceutically acceptable diluent. 
Postupak priprave tekućeg rotavirusnog pripravka u skladu s bilo kojim patentnih zahtjeva 1 do 31, naznačen time što se sastoji u miješanju rotavirusnog antigena, šećera i karboksilata s farmaceutski prihvatljivim razrjeđivačem. HR P20110668 T1
Installation according to one of claims 1 to 3, characterized in that 
Sistem iz patentnih zahtjeva od 1 do 3, u okviru kojega:
In an embodiment, the particle contrast agent composition can further include a phosphate buffered saline including at least sodium phosphate dibasic and potassium phosphate monobasic. 
Pripravak prema zahtjevu 3, naznačen time da dodatno sadrži: fosfatno puferiranu fiziološku otopinu koja obuhvaća barem dvobazni natrijev fosfat i monobazni kalijev fosfat.
reducing the above compound of formula XIa to obtain a compound of formula Va in the form of diastereoisomeric mixture (S,R+R,R) and, if desired, separating the compound of formula Va (S,R+R,R) into the single diastereomer Va (S,R) and the single diastereomer Va (R,R). The process for preparing l -NBV of formula comprises: 
X) redukciju navednog spoja formule Xla, da bi se dobio spoj formule Va prema zahtjevu 1 u obliku dijasteroizomerne smjese (S, R+R, R) i, po želji, odvajanje smjese formule Va (S, R+R, R) na zaseban 15 dijasteromer Va (S, R) i zaseban dijasteromer Va (R, R).
Cyclophosphamide, hydroxydoxorubicin, vincristine are given by intravenous injection; prednisone is given by oral tablet. 
daju intravenoznom injekcijom; prednison se daje oralnom tabletom. g Ne-Hodgkinov limfom.
An antibody-like binding protein comprising four polypeptide chains that form four antigen binding sites, wherein two polypeptide chains have a structure represented by the formula: 
Protutijelu sličan vezivni protein koji sadrži četiri polipeptidna lanca koji tvore četiri mjesta vezanja antigena, pri čemu dva polipeptidna lanca imaju strukturu predstavljenu s formulom:
A method according to claim 1 or claim 2, wherein the oxygen level of gas exiting the apparatus is maintained within the 1-16% range. 
Metoda prema zahtjevu 1 ili 2, naznačena time da se razina kisika u plinu koji izlazi iz uređaja održava unutar raspona od 1-16%.